Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Change in Cash (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Change in Cash for 3 consecutive years, with -$7.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 13.61% to -$7.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$32.7 million, a 292.82% decrease, with the full-year FY2024 number at $12.4 million, up 215.05% from a year prior.
  • Change in Cash was -$7.0 million for Q3 2025 at Mereo BioPharma, up from -$7.8 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $38.9 million in Q2 2024 to a low of -$9.7 million in Q4 2024.
  • A 3-year average of -$1.9 million and a median of -$7.8 million in 2025 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 605.76% in 2024; the steepest drop was 169.34% in 2024.
  • Mereo BioPharma's Change in Cash stood at -$5.1 million in 2023, then crashed by 89.76% to -$9.7 million in 2024, then increased by 27.69% to -$7.0 million in 2025.
  • Per Business Quant, the three most recent readings for MREO's Change in Cash are -$7.0 million (Q3 2025), -$7.8 million (Q2 2025), and -$8.2 million (Q1 2025).